MNOV MediciNova, Inc.
$1.40▲ +0.03%
Healthcare
Other
Volume 16.1K
Avg Volume (10D) 55.4K
Key Metrics & Fundamentals
Market Cap
$68.93M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.20 - 3.90
% vs 50 MA
-21.77%
% vs 200 MA
-7.56%
RSI-14
38.4
MACD Histogram
+0.0100
Beta (1Y vs SPY)
0.80
Free Cash Flow
-$1.92M
Gross Rev
$458,439
Gross Profit
$317,759
EBITDA
-$2.54M
COGS
$140,680
Operating Exp
$2.86M
Operating Income
-$2.54M
EBIT
-$2.54M
Pretax Income
-$2.31M
Net Income
-$2.31M
EPS (Diluted)
-0.05
Price & Volume History
Loading chart…
Recent News
MediciNova Phase 2 Trial in Fatty Liver Disease Drug Misses Primary Endpoints
MT Newswires · Oct 12, 2026 7:11 AM ET
MediciNova CEO Provides Shareholder Update
GlobeNewswire · Oct 12, 2026 6:00 AM ET
MediciNova to Participate in the Maxim Growth Summit
GlobeNewswire · Oct 6, 2026 6:00 AM ET
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
Benzinga · Sep 28, 2026 11:10 AM ET
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints
InvestorsHub · Sep 28, 2026 9:58 AM ET
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
Investing.com · Sep 28, 2026 9:20 AM ET
Top Premarket Decliners
MT Newswires · Sep 28, 2026 7:44 AM ET
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
GlobeNewswire · Sep 28, 2026 6:00 AM ET
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Stocktwits · Sep 24, 2026 11:23 PM ET
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
GlobeNewswire · Sep 24, 2026 6:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See MNOV's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.